# TDM-optimized Teicoplanin Dosing Versus Standard of Care

> **NCT05914467** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Radboud University Medical Center** · enrollment: 74 (estimated)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Teicoplanin

## Key facts

- **NCT ID:** NCT05914467
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05914467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05914467, "TDM-optimized Teicoplanin Dosing Versus Standard of Care". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05914467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*